Research Analysts’ Updated EPS Estimates for May, 22nd (1COV, AMAT, DB1, DCI, DXC, NLSN, QEP, RRC, SOL, UNICY)

Share on StockTwits

Research Analysts’ updated eps estimates for Wednesday, May 22nd:

Covestro (ETR:1COV) was given a €48.00 ($55.81) target price by analysts at Baader Bank. The firm currently has a sell rating on the stock.

Applied Materials (NASDAQ:AMAT) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Applied Materials reported strong fiscal second-quarter results on the back of strong demand for products, new technologies and innovation strategy. The company is riding on its inflection-focused innovation strategy which continues to be the primary growth driver. Further, technological advancements in semiconductor and display areas remain major positives. Also, robust 3D NAND and patterning equipment remain positives. The company remains confident on the opportunities beyond semiconductors, especially in mobile OLEDS and large screen televisions. However, the company’s high fixed cost structure remains a concern for its margin expansion. Further, a slowing smartphone market, especially in China, and its impact on chip demand remains an overhang. Notably, the shares of Applied Materials have underperformed the industry it belongs to over a year.”

Deutsche Boerse (ETR:DB1) had its neutral rating reaffirmed by analysts at DZ Bank AG.

Donaldson (NYSE:DCI) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Over the past three months, Donaldson's shares have underperformed the industry. Also, it looks significantly overvalued compared with the industry over the same time frame. Rising costs of revenues on account of material price inflation and soaring freight charges remain concerns for near-term margins. It anticipates that continued material price inflation and soaring freight charges will hurt gross profit by $30 million in fiscal 2019. Weakening Gas Turbine Systems business is also weighing on the company. Donaldson perceives that this issue will continue to weigh over the top-line performance of its Industrial Products segment in fiscal 2019. Moreover, increase in debt levels can increase financial obligations. In the past 30 days, earnings estimates for the company have declined for fiscal 2020.”

DXC Technology (NYSE:DXC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “DXC Technology is benefiting from strength in the Digital business, which expects further boost from the impending acquisition of Luxoft. The company’s traction in the cloud, and partnerships with HCL, AT&T, VMware and Microsoft are likely to drive growth. Cost saving initiatives like the Bionix program are boosting the bottom line. Strong demand for its operational technology security solutions in the manufacturing and energy sectors is driving its security business. The company pulled off positive earnings surprises in the recent quarters. However, declining legacy application services business is a concern.  Margins at the GBS segment are expected to contract due to DXC Technology’s continued investments in digital hiring and expansion of digital transformation capabilities. The company also expects currency headwinds to be an overhang on the top line. Shares have underperformed the industry year to date.”

Nielsen (NYSE:NLSN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Nielsen reported better-than-expected earnings in the first quarter driven by solid execution and ongoing focus on operational efficiency. The company is benefiting from strength in both the segments, namely Global Media and Connect. We believe the company’s consistent investment in product portfolio, and growing client adoption are expected to continue aiding business growth in the near term as well as long haul. Further, positive contributions from its acquisitions are positives. However, Nielsen is being impacted by unimpressive performance in the emerging-markets served. The company’s ongoing investments in technology and infrastructure remain risks for margin expansion and profitability. Mounting competition in the digital space poses a major threat to its market position. Notably, in a year’s time, the stock has underperformed the industry it belongs to.”

QEP Resources (NYSE:QEP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “QEP Resources' quality acreage in the prolific Permian Basin bodes well for its production prospects. Moreover, the company  maintains a very competitive cost structure, which contributes to the consistency of its growth and returns. Additionally, QEP Resources has an active stock buyback program, which increases shareholders' value. However, cost inflation in the Permian Basin is a concern for the company. Also, the shortage in takeaway capacity in the basin can impact QEP Resources’ output and profitability. Moreover, the company has a weak balance sheet. Therefore, the stock warrants a cautious stance.”

Range Resources (NYSE:RRC) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Range Resources has extensive oil and gas resources in key regions like Marcellus and North Louisiana. The company is advantageously positioned to benefit in the long run from its projects in the Appalachian Basin. Moreover, its 2019 capital budget is set below the 2018 level, while production is expected to surge, reflecting capital efficiency improvement. It is also well positioned to capitalize the mounting demand for clean energy. However, rising costs and expenses are a concern for the company. Also, its lower-than-industry dividend yield is unattractive. Balance sheet weakness of the company can also bar its financial flexibility. As such, the stock warrants a cautious stance.”

ReneSola (NYSE:SOL) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “ReneSola’s revenue growth prospects from the nation seems bleak, with the U.S. administration having imposed a tariff of 30% on the import of solar panels and modules. Solar industry trends and market volatility along with unfavorable changes in supply and demand for solar power products throughout the value chain may pose potential threats to the business. A significant portion of ReneSola’s revenues is denominated in foreign currencies. As the company expands its distribution network internationally, its exposure to fluctuations in currency exchange rates rises, which may impact its financial performance. Over the past year, its share price has underperformed its industry. However, ReneSola continues to benefit from a steady flow of contracts from both domestic and international customers. It is also focused on monetizing its project portfolio, while looking for opportunities to expand pipeline across key markets.”

UNICHARM CORP/S (OTCMKTS:UNICY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Unicharm Corporation primarily manufactures and sells baby and child care, feminine care, healthcare, cosmetic, household and pet care products. The Product portfolio includes Baby products which consist of Diapers, Swimming pants, Baby Wipes and Wet tissues. Feminine hygiene product consists of Napkins, Tampons, underwear and feminine care products. Household product comprises cleaning sheets, wet tissues, cosmetic puffs, anti-per spirant product and paper towel. Urinary Products includes Gentle Skin type, Pantiliner type and Incontinence Pants. It also consist mask and nursing care products. The company operates primarily in Europe, Asia, North America, Middle East and Africa and Oceania. Unicharm Corporation is headquartered in Tokyo, Japan. “

Urovant Sciences (NASDAQ:UROV) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company’s product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. “

Vaccinex (NASDAQ:VCNX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

Receive News & Ratings for Covestro AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covestro AG and related companies with MarketBeat.com's FREE daily email newsletter.